Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Urinary Bladder Neoplasms 4 Glioma 4 Prostatic Neoplasms 3 Multiple Myeloma 3 Wilms Tumor 2 Rhabdoid Tumor 2 Non-Muscle Invasive Bladder Neoplasms 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Neoplasms 2 Medulloblastoma 2 Lymphoma, Non-Hodgkin 2 Lymphoma 2 Lung Neoplasms 2 Histiocytosis, Langerhans-Cell 2 Hepatoblastoma 2 Esophageal Neoplasms 2 Ependymoma 2 Central Nervous System Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Xanthogranuloma, Juvenile 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Thyroid Neoplasms 1 Stomach Neoplasms 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Recurrence 1

Interventions

toripalimab 2 Injections 2 ulixertinib 1 tislelizumab 1 spartalizumab 1 lenvatinib 1 famitinib 1 erdafitinib 1 camrelizumab 1 Oxaliplatin 1 Leucovorin 1 Irinotecan 1 Gemcitabine 1 Docetaxel 1 Cisplatin 1 Capecitabine 1 5-fluorouridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Solid Tumor × erdafitinib × Clear all

NCT04083976 2026-05-04

RAGNAR

Janssen Research & Development, LLC

Phase 2 Completed

316 enrolled 15 charts

Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡